Edgewise Therapeutics, Inc. (EWTX): who owns it and who trades it
As of Nov 16, 2026, EWTX insiders reported 33 open-market sales worth $17.6M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Alan J Russell (Director), with $8.1M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Edgewise Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns EWTX
225 funds and institutions reported EWTX shares worth $4.9B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Orbimed Advisors LLC with 14.4%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Orbimed Advisors LLC | 15.52M | 14.42% | $631M | No change |
| Paradigm Biocapital Advisors LP | 10.22M | 9.49% | $415M | +39% |
| Ra Capital Management, L.P. | 8.39M | 7.80% | $341M | -20% |
| BlackRock, Inc. | 6.61M | 6.14% | $268M | +2% |
| Jupiter Topco LLC | 6.08M | 5.65% | $247M | – |
| FMR LLC (Fidelity) | 5.49M | 5.10% | $223M | +440% |
| Novo Holdings A/s | 5.35M | 4.97% | $217M | No change |
| Driehaus Capital Management LLC | 4.73M | 4.39% | $192M | +6% |
| Perceptive Advisors LLC | 4.37M | 4.07% | $178M | -1% |
| Vanguard Capital Management LLC | 3.86M | 3.59% | $157M | +2% |
| Baker Bros. Advisors LP | 3.70M | 3.44% | $150M | -44% |
| Siren, L.L.C. | 3.18M | 2.96% | $129M | -28% |
| California State Teachers Retirement System | 2.90M | 2.69% | $71.3M | +3846% |
| Cormorant Asset Management, LP | 2.51M | 2.33% | $102M | -23% |
| Geode Capital Management, LLC | 2.17M | 2.02% | $88.3M | +21% |
| Alliancebernstein L.P. | 2.12M | 1.97% | $66.7M | +23% |
| Integral Health Asset Management, LLC | 2.00M | 1.86% | $81.3M | +25% |
| Braidwell LP | 2.00M | 1.86% | $81.1M | -15% |
| Morgan Stanley | 1.95M | 1.81% | $79.2M | -13% |
| State Street Corp | 1.83M | 1.70% | $74.3M | +6% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, EWTX insiders reported $0 of open-market purchases and $17.6M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Michael Nofi | CFO | Sale | 4,442 | $45.43 | $202K | Form 4 |
| Aug 13, 2026 | Joanne M. Donovan | CMO | Sale | 2,919 | $43.41 | $127K | Form 4 |
| Aug 12, 2026 | Joanne M. Donovan | CMO | Sale | 800 | $44.52 | $35.6K | Form 4 |
| Aug 12, 2026 | Joanne M. Donovan | CMO | Sale | 104 | $44.43 | $4.6K | Form 4 |
| Aug 12, 2026 | Joanne M. Donovan | CMO | Sale | 2,779 | $43.71 | $121K | Form 4 |
| Aug 12, 2026 | Joanne M. Donovan | CMO | Sale | 2,839 | $43.78 | $124K | Form 4 |
| Aug 12, 2026 | Alan J Russell | Director | Sale | 3,238 | $43.68 | $141K | Form 4 |
| Aug 12, 2026 | Alan J Russell | Director | Sale | 390 | $44.46 | $17.3K | Form 4 |
| Aug 12, 2026 | Alan J Russell | Director | Sale | 2,273 | $43.68 | $99.3K | Form 4 |
| Aug 12, 2026 | John R Moore | General Counsel | Sale | 2,439 | $43.81 | $107K | Form 4 |
| Aug 12, 2026 | John R Moore | General Counsel | Sale | 59 | $44.41 | $2.6K | Form 4 |
| Aug 12, 2026 | John R Moore | General Counsel | Sale | 99 | $44.50 | $4.4K | Form 4 |
| Aug 12, 2026 | John R Moore | General Counsel | Sale | 2,419 | $43.80 | $106K | Form 4 |
| Aug 12, 2026 | Behrad Derakhshan | Chief Business Officer | Sale | 150 | $44.44 | $6.7K | Form 4 |
| Aug 12, 2026 | Behrad Derakhshan | Chief Business Officer | Sale | 2,475 | $43.70 | $108K | Form 4 |
| Aug 12, 2026 | Behrad Derakhshan | Chief Business Officer | Sale | 304 | $44.50 | $13.5K | Form 4 |
| Aug 12, 2026 | Behrad Derakhshan | Chief Business Officer | Sale | 2,171 | $43.79 | $95.1K | Form 4 |
| Aug 12, 2026 | Kevin Koch | CEO | Sale | 8,276 | $43.66 | $361K | Form 4 |
| Aug 12, 2026 | Kevin Koch | CEO | Sale | 8,782 | $43.64 | $383K | Form 4 |
| Aug 12, 2026 | Kevin Koch | CEO | Sale | 913 | $44.33 | $40.5K | Form 4 |
| Jul 1, 2026 | Alan J Russell | Director | Sale | 69,648 | $39.41 | $2.7M | Form 4 |
| Jul 1, 2026 | Alan J Russell | Director | Sale | 130,352 | $39.41 | $5.1M | Form 4 |
| May 5, 2026 | Joanne M. Donovan | CMO | Sale | 50,000 | $38.57 | $1.9M | Form 4 |
| May 4, 2026 | Joanne M. Donovan | CMO | Sale | 5,230 | $31.29 | $164K | Form 4 |
| Apr 1, 2026 | Joanne M. Donovan | CMO | Sale | 28,662 | $32.31 | $926K | Form 4 |
| Mar 31, 2026 | Joanne M. Donovan | CMO | Sale | 21,338 | $32.12 | $685K | Form 4 |
| Mar 27, 2026 | Joanne M. Donovan | CMO | Sale | 9,623 | $30.98 | $298K | Form 4 |
| Mar 27, 2026 | Joanne M. Donovan | CMO | Sale | 6,735 | $30.98 | $209K | Form 4 |
| Jan 21, 2026 | Badreddin Edris | Director | Sale | 13,690 | $29.44 | $403K | Form 4 |
| Jan 21, 2026 | Badreddin Edris | Director | Sale | 66,477 | $29.44 | $2M | Form 4 |
| Jan 21, 2026 | Badreddin Edris | Director | Sale | 10,463 | $29.44 | $308K | Form 4 |
| Jan 21, 2026 | Badreddin Edris | Director | Sale | 17,236 | $29.44 | $507K | Form 4 |
| Jan 21, 2026 | Badreddin Edris | Director | Sale | 7,605 | $29.44 | $224K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Alan J Russell | Chief Scientific Officer, Director | – | $8.1M | Aug 12, 2026 |
| Joanne M. Donovan | CMO | – | $4.6M | Aug 13, 2026 |
| Badreddin Edris | Director | – | $3.4M | Jan 21, 2026 |
| Kevin Koch | President and CEO, Director | – | $785K | Aug 12, 2026 |
| Behrad Derakhshan | Chief Business Officer | – | $223K | Aug 12, 2026 |
| John R Moore | General Counsel | – | $220K | Aug 12, 2026 |
| Michael Nofi | Chief Financial Officer | – | $202K | Nov 10, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
EWTX short interest
High short interest. 11.7% of EWTX shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went up 23%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 12.70M EWTX shares were sold short, 11.7% of the shares outstanding, up 8.0% from the report before. At the average daily volume of 1.32M shares, buying them all back would take about 9.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 12.70M | 11.69% | +8% | 1.32M | 9.6 |
| Oct 15, 2026 | 11.75M | 10.82% | +5% | 1.39M | 8.5 |
| Sep 30, 2026 | 11.22M | 10.34% | +18% | 2.00M | 5.6 |
| Sep 15, 2026 | 9.54M | 8.79% | +2% | 1.19M | 8.0 |
| Aug 31, 2026 | 9.35M | 8.61% | -3% | 1.16M | 8.0 |
| Aug 14, 2026 | 9.68M | 8.91% | -2% | 1.51M | 6.4 |
| Jul 31, 2026 | 9.84M | 9.06% | -2% | 815,024 | 12.1 |
| Jul 15, 2026 | 10.07M | 9.36% | -4% | 1.21M | 8.3 |
| Jun 30, 2026 | 10.49M | 9.75% | +6% | 2.08M | 5.0 |
| Jun 15, 2026 | 9.93M | 9.23% | -9% | 1.74M | 5.7 |
| May 29, 2026 | 10.91M | 10.14% | +5% | 982,747 | 11.1 |
| May 15, 2026 | 10.35M | 9.62% | +2% | 1.48M | 7.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Edgewise Therapeutics company events
Edgewise Therapeutics filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 13, 2026DealEdgewise Therapeutics, Inc. completed the previously announced acquisition of the Company’s sevasemten compound and certain other related assets collectively constituting the Company’s muscular dystrophy program by Servier Pharmaceuticals LLC and Les Laboratoires Servier (together, the “Buyers”… Filing
- Jun 5, 2026VoteReported shareholder vote results. Filing
- Jun 1, 2026AgreementEdgewise Therapeutics, Inc., announced its entry into an Asset Purchase Agreement with Servier Pharmaceuticals LLC and Les Laboratoires Servier (together, the “Buyers”) on May 31, 2026. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Nov 20, 2025LeadershipThe Board of Directors of Edgewise Therapeutics, Inc. appointed Christopher Martin to serve as a Class I director, with a term expiring at the Company’s 2028 annual meeting of stockholders. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Edgewise Therapeutics financials
Famous investors that hold EWTX
3 of the 50 well-known investors we track reported holding EWTX in their latest 13F filing. The largest position is Ken Griffin's, worth $104M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.57M | $104M | 0.1% | +447% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 58,531 | $2.4M | 0.0% | +3% |
| Israel Englander · Millennium Management | Q3 2026 | 33,479 | $1.4M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named EWTX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 6.7% |
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 6.7% |
| Nov 5, 2026 | FMR LLC | 13G/A | 0.9% |
| Nov 5, 2026 | FMR LLC | 13G/A | 0.9% |
Questions about Edgewise Therapeutics, Inc. (EWTX) stock
Who owns the most EWTX stock?
The largest reported owner of Edgewise Therapeutics, Inc. (EWTX) is Orbimed Advisors LLC, with 14.4% of the company. In total, 225 funds and institutions reported holding EWTX at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are EWTX insiders buying or selling?
In the last 12 months, EWTX insiders reported no open-market purchases and 33 sales worth $17.6M. The latest trade was on Nov 10, 2026. See every trade.
What is the short interest in EWTX?
As of Oct 30, 2026, 12.70M EWTX shares were sold short, 11.7% of the shares outstanding, up 8.0% from the report before. At the average daily volume of 1.32M shares, buying them all back would take about 9.6 trading days (days to cover). See the history.
Which famous investors hold EWTX?
3 of the 50 well-known investors we track reported EWTX in their latest 13F filing, including Ken Griffin, Paul Tudor Jones, Israel Englander. The largest position is worth $104M. See all holders.
Executive pay
Edgewise Therapeutics's chief executive was paid a total of $7.4M for the year ended Dec 31, 2025, down 3% from $7.6M the year before. In the last 12 months, Edgewise Therapeutics's executives and directors bought no stock on the open market and sold $17.6M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.